These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 10955804

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Inverse correlation between expression of multidrug resistance gene and N-myc oncogene in human neuroblastomas.
    Nakagawara A, Kadomatsu K, Sato S, Kohno K, Takano H, Akazawa K, Nose Y, Kuwano M.
    Cancer Res; 1990 May 15; 50(10):3043-7. PubMed ID: 2185879
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.
    Shimada H, Nakagawa A, Peters J, Wang H, Wakamatsu PK, Lukens JN, Matthay KK, Siegel SE, Seeger RC.
    Cancer; 2004 Oct 15; 101(8):1873-81. PubMed ID: 15386308
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Expression of N-myc and c-src protooncogenes correlating to the undifferentiated phenotype and prognosis of primary neuroblastomas.
    Matsunaga T, Takahashi H, Ohnuma N, Tanabe M, Yoshida H, Iwai J, Shirasawa H, Simizu B.
    Cancer Res; 1991 Jun 15; 51(12):3148-52. PubMed ID: 2039993
    [Abstract] [Full Text] [Related]

  • 9. Trk mRNA and low affinity nerve growth factor receptor mRNA expression and triploid DNA content in favorable neuroblastoma tumors.
    Kogner P, Barbany G, Björk O, Castello MA, Donfrancesco A, Falkmer UG, Hedborg F, Kouvidou H, Persson H, Raschella G.
    Prog Clin Biol Res; 1994 Jun 15; 385():137-45. PubMed ID: 7972205
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. High Skp2 expression characterizes high-risk neuroblastomas independent of MYCN status.
    Westermann F, Henrich KO, Wei JS, Lutz W, Fischer M, König R, Wiedemeyer R, Ehemann V, Brors B, Ernestus K, Leuschner I, Benner A, Khan J, Schwab M.
    Clin Cancer Res; 2007 Aug 15; 13(16):4695-703. PubMed ID: 17652624
    [Abstract] [Full Text] [Related]

  • 14. Differential expression of pleiotrophin and midkine in advanced neuroblastomas.
    Nakagawara A, Milbrandt J, Muramatsu T, Deuel TF, Zhao H, Cnaan A, Brodeur GM.
    Cancer Res; 1995 Apr 15; 55(8):1792-7. PubMed ID: 7712489
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Association among EPHB2, TrkA, and MYCN expression in low-stage neuroblastomas.
    Tang XX, Evans AE, Zhao H, Cnaan A, Brodeur GM, Ikegaki N.
    Med Pediatr Oncol; 2001 Jan 15; 36(1):80-2. PubMed ID: 11464911
    [Abstract] [Full Text] [Related]

  • 18. Induction of N-myc in neuroblastoma by autocrine IGF-II depends on farnesylated Ras. Application of farnesyltransferase inhibitors.
    Wittrock J, Schweizer P, Girgert R.
    Anticancer Res; 2002 Jan 15; 22(6C):4205-9. PubMed ID: 12553057
    [Abstract] [Full Text] [Related]

  • 19. Expression of multiple drug resistance gene, MDR1, and N-myc oncogene in an Italian population of human neuroblastoma patients.
    Corrias MV, Cornaglia-Ferraris P, Di Martino D, Stenger AM, Lanino E, Boni L, Tonini GP.
    Anticancer Res; 1990 Jan 15; 10(4):897-902. PubMed ID: 1974410
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.